Cargando…

The clinical utility of newer antidepressant agents: Understanding the role in management of MDD

Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 or...

Descripción completa

Detalles Bibliográficos
Autor principal: Waters, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Psychiatric Pharmacists 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645287/
https://www.ncbi.nlm.nih.gov/pubmed/36405509
http://dx.doi.org/10.9740/mhc.2022.10.309
_version_ 1784826933714878464
author Waters, Kristin
author_facet Waters, Kristin
author_sort Waters, Kristin
collection PubMed
description Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases.
format Online
Article
Text
id pubmed-9645287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association of Psychiatric Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-96452872022-11-18 The clinical utility of newer antidepressant agents: Understanding the role in management of MDD Waters, Kristin Ment Health Clin Psychopharmacology Pearls Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases. American Association of Psychiatric Pharmacists 2022-11-03 /pmc/articles/PMC9645287/ /pubmed/36405509 http://dx.doi.org/10.9740/mhc.2022.10.309 Text en © 2022 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Psychopharmacology Pearls
Waters, Kristin
The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
title The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
title_full The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
title_fullStr The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
title_full_unstemmed The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
title_short The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
title_sort clinical utility of newer antidepressant agents: understanding the role in management of mdd
topic Psychopharmacology Pearls
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645287/
https://www.ncbi.nlm.nih.gov/pubmed/36405509
http://dx.doi.org/10.9740/mhc.2022.10.309
work_keys_str_mv AT waterskristin theclinicalutilityofnewerantidepressantagentsunderstandingtheroleinmanagementofmdd
AT waterskristin clinicalutilityofnewerantidepressantagentsunderstandingtheroleinmanagementofmdd